Shares of Rhoen Klinikum AG (ETR:RHK) have been assigned a consensus rating of “Sell” from the seven analysts that are covering the stock, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a sell rating and three have issued a hold rating on the company. The average 12 month target price among analysts that have covered the stock in the last year is €21.96 ($25.53).
Several brokerages have recently commented on RHK. Credit Suisse Group set a €16.50 ($19.19) target price on Rhoen Klinikum and gave the stock a “sell” rating in a report on Monday, August 5th. Berenberg Bank set a €26.20 ($30.47) price target on Rhoen Klinikum and gave the company a “neutral” rating in a research note on Tuesday, July 30th. Finally, Independent Research set a €25.50 ($29.65) price target on Rhoen Klinikum and gave the company a “neutral” rating in a research note on Monday, August 5th.
RHK opened at €21.80 ($25.35) on Tuesday. The stock has a market cap of $1.46 billion and a PE ratio of 28.17. The company has a current ratio of 1.80, a quick ratio of 1.66 and a debt-to-equity ratio of 9.80. Rhoen Klinikum has a 1 year low of €21.06 ($24.49) and a 1 year high of €27.40 ($31.86). The stock’s 50 day simple moving average is €22.98 and its 200-day simple moving average is €24.95.
About Rhoen Klinikum
RHÖN-KLINIKUM Aktiengesellschaft, together with its subsidiaries, builds, acquires, and operates primarily acute-care hospitals in Germany. Its hospitals offer treatment services primarily in the areas of cardiovascular, neurology, oncology, pulmonology, orthopedic, accident surgery; rehabilitation and nursing services to the elderly; and thoracic, tumors, and psychosomatic, as well as spinal, column, and joints diseases.
Recommended Story: What is Forex?
Receive News & Ratings for Rhoen Klinikum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhoen Klinikum and related companies with MarketBeat.com's FREE daily email newsletter.